Multiple Daily Injections

Mechanism

Related News

Tandem Diabetes Wins CE Mark for AID Systems in Europe After FDA Pregnancy Approval

Jun 05, 2026

Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.

MannKind Wins FDA Approval for Afrezza Inhaled Insulin in Children Ages 6 and Older

May 31, 2026

MannKind Corporation announced FDA approval of Afrezza inhaled mealtime insulin for pediatric patients with diabetes ages 6 and older. The approval makes Afrezza the first needle-free mealtime insulin alternative for children in over 100 years. Eligible patients can access Afrezza for $35 or less per month.